In this issue:
- Risk of decompensation and mortality with carvedilol in compensated cirrhosis
- Semaglutide, cilofexor and firsocostat for NASH
- Māori experiences of direct-acting antiviral HCV treatment
- Vebicorvir for chronic HBV infection
- Small-interfering RNA for chronic HBV
- Bulevirtide + TDF for HBV/HDV coinfection
- Drug-drug interactions between direct-acting antivirals and co-medications
- Cost analysis of automated HCV screening in the emergency department
- Prison-based interventions for HCV elimination
- Reinfection and risk behaviours during opioid agonist therapy
Please login below to download this issue (PDF)